|
PF-52474 |
INCRUSE ELLIPTA 62.5 mcg/dosis Polvo para inhalación |
2025-09-29 |
|
Glaxo Group Ltd. |
Reino Unido
|
J.I.Cohen, S.A. |
Amicelco |
Glaxosmithkline Guatemala |
Centro Distribuidor, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-52525 |
TAFINLAR 50 mg Cápsulas |
2025-11-03 |
|
Novartis Pharma AG |
Reino Unido
|
J.I.Cohen, S.A. |
Novartis Farmacéutica, Sociedad Anónima (América Central) |
Norvanda Healthcare, Sociedad Anónima |
Agefinsa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-52526 |
TAFINLAR 75 mg Cápsulas |
2025-11-03 |
|
Novartis Pharma AG |
Reino Unido
|
J.I.Cohen, S.A. |
Novartis Farmacéutica, Sociedad Anónima (América Central) |
Norvanda Healthcare, Sociedad Anónima |
Agefinsa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53572 |
TRIUMEQ Comprimidos recubiertos con película |
2026-08-20 |
|
ViiV Healthcare UK Limited |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53632 |
ZEMPLAR 5 mcg/mL Solución Inyectable |
2021-12-20 |
|
AbbVie Ltd. |
Reino Unido
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Abbvie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-53880 |
INDOXYL Gel Tópico |
2026-11-26 |
|
Glaxosmithkline UK Limited. |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56770 |
TIVICAY 25 mg Tabletas recubiertas |
2024-05-31 |
|
ViiV Healthcare UK Limited |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56771 |
TIVICAY 10 mg Tabletas recubiertas |
2024-05-31 |
|
ViiV Healthcare UK Limited |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-34661 |
SERETIDE DISKUS 50-250mcg/dosis Polvo para Inhalación. |
2019-12-18 |
|
Glaxo Wellcome UK Limited |
Reino Unido
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-34663 |
ZIAGEN 300 mg tabletas recubiertas |
2020-01-06 |
|
ViiV Healthcare UK Limited |
Reino Unido
|
J.I.Cohen, S.A. |
Amicelco |
Glaxosmithkline Guatemala |
Centro Distribuidor, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|